BioSpace News Archive

Generation Bio Co. today provided an update on factor VIII expression from a series of mouse and companion non-human primate (NHP) studies in hemophilia A, as well as an update on the development of its non-viral genetic medicine platform.

In the open-label LUMINARY Study, SAGE-718 improved performance from baseline on multiple tests of cognitive function in patients with Alzheimer’s disease mild cognitive impairment and mild dementia, consistent with positive signals seen in Parkinson’s disease and Huntington’s disease.

Galera Therapeutics, Inc. (Nasdaq: GRTX), today announced that corrected results from its Phase 3 ROMAN trial of avasopasem for the treatment of RT-induced severe oral mucositis (SOM) in patients with locally advanced head and neck cancer (HNC) achieved statistical significance on the primary endpoint of reduction in the incidence of SOM.

Cabaletta Bio, Inc. today reported top-line data on biologic activity from the two lowest dose cohorts in the DesCAARTes™ Phase 1 clinical trial of DSG3-CAART for the treatment of patients with mucosal Pemphigus Vulgaris (mPV).

Centene Corporation (NYSE: CNC) (“Centene”) today announced Chairman and CEO Michael Neidorff’s intent to retire in 2022 as CEO. Upon his retirement as CEO, he will serve as Executive Chairman until the end of 2022.

Rational Vaccines today announced the launch of a clinical trial designed to investigate the disease burden of herpes simplex virus types 1 and 2 (HSV-1 and HSV-2) in patients with HIV infection.

Lead investigators from clinical trials evaluating eprenetapopt in patients with TP53 mutant MDS or AML presented positive, updated data at the 2021 ASH Annual Meeting.

Affinia Therapeutics today announced the appointment of Thomas (Tommy) Leggett as Chief Financial Officer (CFO).

electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today provided an update on the ongoing clinical research to assess the potential of gammaCore (non-invasive vagal nerve stimulation; nVNS) to treat Post Traumatic Stress Disorder (“PTSD”).

Erasca, Inc. today announced that the company has been added to the NASDAQ Biotech Index (Nasdaq: NBI), effective prior to market open on Monday, December 20, 2021.